The leader of the U.S. healthcare services and insurance market has had a few difficult quarters behind it. However, the latest results seem to indicate that the company’s fortunes may finally be turning around. Q1 results beat investors’ expectations, and the stock is up nearly 10% in today’s session.
- The company reported revenue of USD 111.7 billion. This represents an approximately 2% year-on-year increase and is above analysts’ expectations of around USD 109 billion.
Where the company truly stood out was profitability and guidance.
- EPS came in as high as USD 7.23 versus expectations of around USD 6.6, representing a 5% increase.
- Full-year EPS guidance was raised from USD 17.75 to USD 18.25, which is well above the Wall Street consensus of about USD 17.8.
Investors are also focusing on the company’s medical cost ratio, a key metric in this business. A decline (optimization) in medical costs translates into improved profitability of the business model. The company managed to bring the medical cost ratio down to 83.9%, a direct improvement in profitability.
Against the backdrop of rising demand for healthcare services in the U.S., the base effect and the impressive improvement in profitability may help the company decisively put a difficult period behind it.
UNH.US (D1)
The stock price has returned to the area near the upper boundary of the consolidation channel. A prerequisite for further gains is a clear breakout above the broad, strong resistance zone between 360 and 380. If that happens, the price may “chase” the rising trendline (orange). Source: xStation5.
US Open: Macro Up, Tensions Down!
Defense sector earnings: RTX, Thales and Northrop Grumman
USA Rare Earth Acquires Key Brazilian Rare Earth Metal Mines ⛏️
US OPEN: Return of geopolitical concerns hits markets 💥
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
